Fresenius Kabi Adds Additional Strengths to Adenosine Product Line

Fresenius Kabi announced the launch of Adenosine Injection, USP in 60mg/20mL and 90mg/30mL dosage strengths, as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.

Adenosine Injection is also available from Fresenius Kabi in 6mg/2mL and 12mg/4mL strengths for the treatment of paroxysmal supraventricular tachycardia, including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).

“With the extension of our Adenosine product line, Fresenius Kabi is pleased to offer another essential product to support cardiac care in hospitals and cardiology centers for their patient care needs,” said John Ducker, president and CEO of Fresenius Kabi USA.

For more information call (800) 551-7176 or visit Fresenius-Kabi.com.